The effect of the angiotensin-converting⇓enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction

New England Journal of Medicine

Volumn 332, Issue 2, 1995, Pages 80-85

  Ambrosioni, Ettore ^a   Borghi, Claudio ^a   Magnani, Bruno ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ZOFENOPRIL;

AGED; ARTICLE; BRAIN VENTRICLE DILATATION; CAUSE OF DEATH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; MORBIDITY; MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 0028816282     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199501123320203     Document Type: Article

References (32)

1. Yusuf S, Sleight P, Held P, McMahon S Routine medical management of acute myocardial infarction: lessons from overviews of recent randomized controlled trials. Circulation 1990; 82: Suppl II: II-117
2. Cairns JA, Collins R, Fuster V, Passamani ER Coronary thrombolysis. Chest 1989; 95: Suppl: 73S-87S
3. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986; 2:57-66
4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-360
5. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1:397-402
6. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988; 319:80-86
7. Sharpe N, Murphy J, Smith H, Hannan S Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988; 1:255-259
8. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342:821-828
9. Pfeffer MA, Braunwald E, Moye LA, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327:669-677
10. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-691 [Erratum, N Engl J Med 1992;327:1768.]
11. Hammermeister KE, DeRouen TA, Dodge HT Variables predictive of survival in patients with coronary disease: selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation 1979; 59:421-430
12. White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76:44-51
13. Pfeffer MA, Braunwald E Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990; 81:1161-1172
14. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto MiocardicoGISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343:1115-1122
15. ISIS Collaborative Group. ISIS-4: randomised study of oral captopril in over 50,000 patients with suspected acute myocardial infarction. Circulation 1993; 88: Suppl I: I-394 abstract.
16. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327:678-684
17. Pye M, Oldroyd KG, Ray SG, Effects of early captopril administration on left ventricular dilatation and function after acute myocardial infarction. Circulation 1990; 82: Suppl III: III-674 abstract.
18. Stone PH, Raabe DS, Jaffe AS, Prognostic significance of location and type of myocardial infarction: independent adverse outcome associated with anterior location. J Am Coll Cardiol 1988; 11:453-463
19. DeForrest JM, Waldron TL, Krapcho J, Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. J Cardiovasc Pharmacol 1989; 13:887-894
20. Cushman DW, Wang FL, Fung WC, Harvey CM, DeForrest JM Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens 1989; 2:294-306
21. Ambrosioni E, Borghi C, Magnani B Early treatment of acute myocardial infarction with angiotensin-converting enzyme inhibition: safety considerations. Am J Cardiol 1991; 68: Suppl: 101D-110D
22. van Gilst WH, Scholtens E, de Graeff PA, de Langen CDJ, Wesseling H Differential influences of angiotensin-converting enzyme inhibitors on the coronary circulation. Circulation 1988; 77: Suppl I: I-24
23. Ambrosioni E, Borghi C, Magnani B Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study: rationale, design, organization, and outcome definitions. Control Clin Trials 1994; 15:201-210
24. Madsen EB, Gilpin E, Slutsky RA, Ahnve S, Henning H, Ross J Jr Usefulness of chest x-ray for predicting abnormal left ventricular function after acute myocardial infarction. Am Heart J 1984; 108:1431-1436
25. Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E Early and late angiotensin-converting enzyme inhibition in acute myocardial infarction. Am J Cardiol 1993; 72: Suppl: 169G-174G
26. Simoons ML Myocardial infarction: ACE inhibitors for all? for ever? Lancet 1994; 344:279-281
27. de Graeff PA, van Gilst WH, Bel K, de Langen CDJ, Kingma JH, Wesseling H Concentration-dependent protection by captopril against myocardial damage during ischemia and reperfusion in a closed chest pig model. J Cardiovasc Pharmacol 1987; 9: Suppl 2: S37-S42
28. Sogaard P, Nogaard A, Gotzsche C-O, Ravkilde J, Thygesen K Therapeutic effects of captopril on ischemia and dysfunction of the left ventricle after Q-wave and non-Q-wave myocardial infarction. Am Heart J 1994; 127:1-7
29. Przyklenk K, Kloner RA Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action. Am Heart J 1991; 121:1319-1330
30. Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991; 69:1185-1195
31. Rouleau JL, de Champlain J, Klein M, Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 1993; 22:390-398
32. Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet 1991; 337:872-876 [Erratum, Lancet 1991;337:1174.]